首頁 › 轉移性癌症 › 佛羅里達 › Plantation
Plantation, FL 的 轉移性癌症 臨床試驗
6 項針對 轉移性癌症 的研究正在 Plantation(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
招募中3 期
- Research Site, Plantation
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
招募中1/2 期
- Florida Clinical Trials Group, Plantation
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
招募中1 期
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
招募中3 期
- University of Miami-SCCC-Plantation, Plantation
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
招募中3 期
- BRCR Medical Center, Inc- Internal Medicine, Plantation
其他城市的 轉移性癌症 試驗
- Houston, TX104 項研究
- New York City, NY93 項研究
- Nashville, TN70 項研究
- Boston, MA63 項研究
- Los Angeles, CA57 項研究
- St. Louis, MO54 項研究
- Arlington, VA53 項研究
- Philadelphia, PA46 項研究
- Chicago, IL45 項研究
- San Antonio, TX44 項研究
- Washington, DC43 項研究
- Dallas, TX42 項研究
Plantation 的其他研究
- 非小細胞肺癌16 項研究
- 乳癌14 項研究
- 癌症(所有類型)7 項研究
- 紅斑性狼瘡7 項研究
- 肺癌7 項研究
- 類風濕性關節炎6 項研究
- 前列腺癌5 項研究
- 牛皮癬關節炎5 項研究
- 大腸直腸癌5 項研究
- 黑色素瘤4 項研究
- 多發性骨髓瘤4 項研究
- 小細胞肺癌4 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。